VSE LI MY ZNAEM O VOZMOZhNOSTYaKh LEChENIYa STEROIDNOGO OSTEOPOROZA?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Secondary osteoporosis is closely associated with a number of endocrine diseases. Steroid-induced osteoporosis is the most common form of secondary osteoporosis. The steroid-induced osteoporosis develops due to endogenous hypercortisolism, rather rare, but severe disease. Osteoporosis as one of the dangerous consequences of treatment with pharmacologic doses of glucocorticosteroids (exogenous hypercortisolism) is a more frequent problem. The article discusses the pathogenetic mechanisms of steroid-induced osteoporosis and the influence of an excess of glucocorticosteroids on bone remodeling processes. It is emphasized that the timely appointment of antiresorptive pharmacotherapy in patients with steroid-induced osteoporosis allows to delay or stop the loss of bone mass, and provides low incidence of bone fractures, and bisphosphonates are considered as a first-line therapy for steroid-induced osteoporosis.

Full Text

Restricted Access

About the authors

E. V Biryukova

Email: lena@obsudim.ru

References

  1. Heaney RP. Advances in therapy for osteoporosis. Clin Med Res 2003;1(2):93-9.
  2. Cauley JA, Thompson DE et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
  3. Bouvard B, Audran M, Legrand E, Chappard D. Ultrastructural characteristics of glucocorticoid-induced osteoporosis. Osteoporos Int 2009;20:1089-92.
  4. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006;12(4):436-45.
  5. Риггз Б.Л., Мелтон III Л.Д. Остеопороз. Этиология, диагностика, лечение. М., 2000. 558 с.
  6. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003;15(4):454-57.
  7. Насонова Е.Л. Клинические рекомендации. Ревматология. М., 2010. 282 с.
  8. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Obes Res 1994;2:486-508.
  9. Van Staa T, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis.Osteopros Int 2002;13:777-87.
  10. Van Staa TP, Leufkens HGM, Abenhaim L, Begaud B et al. Use of oral corticosteroids in the United Kingdom. Q J Med 2000;93:105-11.
  11. Van Staa T, Leufkens H, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
  12. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28.
  13. Коршунов Н.И., Ершова О.Б., Белова К.Ю. Глюкокортикоидный остеопороз: диагностика и лечение// РМЖ 2007;6:546-49.
  14. Roche WR, Beasley R, Williams JH. Subepithelial fibrosis in the bronchi of asthmatics text. Lancet 1989;139:520-23.
  15. Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-29.
  16. Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000;106:651-59.
  17. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroidinduced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
  18. Natsui K, Tanaka K, Suda M et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17:105-108.
  19. Peacock M. Calcium metabolism in health and disease. CJASN 2010;5:23-30.
  20. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000;343:1863-75.
  21. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001;2:65-73.
  22. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin.Invest 1998;102:274-82.
  23. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclasts survival and antagonism of bisphosphonate induced osteoclasts apoptosis by glucocorticoids. J Clin invest 2002;109:1041-48.
  24. O'Brien CA, Jia D, Plotkin L, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation. Endocrinology 2004;145:1835-41.
  25. Lane NE, An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001;27:131-36.
  26. Hofbauer LC, Rauner M. Live and let die: effects of glucocorticoids on bone cells. Molec Endocrinol 2009;23:1525-31.
  27. Van Rossum EF, Lamberts SW. Polymorphism in the glucocorticosteroid Receptor gene and their association with metabolic parameters and body composition. Recent Prog Horm Res 2004;59:333-57.
  28. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14(2):279-98.
  29. Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. Bone 2010;46:564-70.
  30. Angeli A, Guglielmi G, Dovio A. et al. High prevalence of asymptomatic vertebral fractures inpost-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone 2000;39:253-59.
  31. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006; 81:662-72.
  32. Дедов И.И., Мельниченко Г.А. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ: Руководство для практикующих врачей., 2006. 1114 с.
  33. Древаль А.В., Марченкова Л.А., Полякова Е.Ю. и др. Состояние костной ткани и риск развития остеопороза у женщин в стадии полной ремиссии болезни Иценко-Кушинга на фоне физиологической менопаузы// Остеопороз и остеопатии, 2007. № 3: С. 8-12.
  34. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis & Rheumatism 2011;63:325-28.
  35. Nancollas GH, Tang R, Gulde S, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27.
  36. Rogers MJ. New insights into molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
  37. Saag KG, Emkey R, Schnitzer TJ. Alendronat for the prevention and treatment of glucorticoid-induced osteoporosis Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-99.
  38. Adachi JD, Saag KG, Delmas PD. et al. Two-year effects of alerndronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, doubl-blind, placebo-controled extension trial. Arthritis Rheum. 2001;44:202-11.
  39. Sambrook PN, Kotowicz M, Nash P. et al. Prevention and treatment of glucorticoid-induced osteoporosis: a comparisonof calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
  40. Recker R, Lips P, Felsenberg D et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Cuop Med Res Opin 2006;22: 1745-55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies